Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The ... Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at ... Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

Internet use among docs increases Medical Marketing and Media Shire's ADHD treatment Vyvanse boasts the most popular product site among pediatricians, and Merck's Januvia took the top spot among primary care physicians ...

Kevin Nalty (aka "Nalts" the YouTube video blogger), who last week decided to quit his job as Consumer Product Director at Merck to "follow his passion" for video, may have been forced into his new career because of videos that were embarrassing to Merck. I mentioned his "ADHD Boy" and "Sucks Away My Will to Live" as examples in a previous post (see " Was Nalty's Fart Video the Straw that Broke Merck's Back or was it Some Other Video? "). Immediately after I posted those videos on this blog, Na